Today we announced the initiation of our Phase 3 clinical trial for our investigational COVID19 vaccine. We are fully focused on developing a safe, effective and urgently-needed preventive solution to people around the world.
Built on a legacy of purpose-driven actions and commitment to diversity and inclusion, we will aim to achieve representation of populations that have been disproportionately impacted by the pandemic in the implementation of our Phase 3 trial program.
Announcing the Awardees in the DR-TB Lifeline QuickFire Challenge
Join us on September 16th for a discussion on how innovators and entrepreneurs from around the world are stepping up and sharing their opinions on how to address this public health challenge. A panel of experts, including a TB survivor, will discuss their views on how creative solutions to the challenges being faced by DR-TB patients can be scaled up with the aim to reach those in need. Awardees of Johnson & Johnson’s DR-TB Lifeline Quickfire Challenge will be announced.
BLUE KNIGHT™ companies announced with aim to improve health security and response
Johnson & Johnson Innovation and BARDA selected seven companies from across the global JLABS portfolio as the initial cohort of Blue Knight residents because of their promising work to fill gaps in the current set of available COVID-19 diagnostic, therapeutic, vaccine and other technology potential solutions.
Johnson & Johnson Signs a Historic Pledge to Uphold the Integrity of the Scientific Process in Developing an Investigational COVID-19 Vaccine
In signing the pledge, we are joining eight other biopharmaceutical companies working on vaccine research and development in making the safety and well-being of vaccinated individuals our top priority.